Shannon M. Conroy

Shannon M. Conroy

Auto-generated profile, based on publicly available information

Shannon M. Conroy

Cancer Prevention Institute of California, Fremont, California

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2014 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
YMY Morimoto
Y Morimoto
SCS M Conroy
S M Conroy
NON J Ollberding
N J Ollberding
YKY Kim
Y Kim
ULU Lim
U Lim
GMGertraud Maskarinec
Gertraud Maskarinec
Ethnic disparities in metabolic disease risk may be the result of differences in circulating adipokines and inflammatory markers related to ethnic variations in obesity and body fat distribution. In a cross-sectional design, we compared serum levels of leptin, adiponectin, C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in control subjects (321 men and 930 women) from two nested case–control studies conducted within the Multiethnic Cohort Study consisting of whites, Japanese Americans (JA), Latinos, African Americans (AA) and Native Hawaiians (NH). General linear models were applied to evaluate ethnic differences in log-transformed serum biomarker levels before and after adjusting for body mass index (BMI) at cohort entry. In comparison to whites, significant ethnic differences were observed for all biomarkers except TNF-α. JA men and women had significantly lower leptin and CRP levels than whites, and JA women also had lower adiponectin levels. Leptin was significantly higher in AA women (P<0.01), adiponectin was significantly lower in AA men and women (P=0.02 and P<0.001), and CRP and IL-6 were significantly higher in AA men and women. Lower adiponectin (P<0.0001) and CRP (P=0.03) levels were the only biomarkers in NH women that differed from whites; no statistically significant differences were seen for NH men and for Latino men and women. When adjusted for BMI at cohort entry, the differences between the lowest and the highest values across ethnic groups decreased for all biomarkers except adiponectin in men indicating that ethnic differences were partially due to weight status. These findings demonstrate the ethnic variations in circulating adipokine and CRP levels before and after adjustment for BMI. Given the limitation of BMI as a general measure of obesity, further investigation with visceral and subcutaneous adiposity measures are warranted to elucidate ethnicity-related differences in adiposity in relation to disparities in obesity-related disease risk.

1 October 2004 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
SCShannon M. Conroy
Shannon M. Conroy
VNVi Nguyen
Vi Nguyen
LQLely A. Quina
Lely A. Quina
PBPenney Blakely-Gonzales
Penney Blakely-Gonzales
CUChristina Ur
Christina Ur
DGDonna L. Gruol
Donna L. Gruol

15 October 1999 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JNJeffrey G. Netzeband
Jeffrey G. Netzeband
SCShannon M. Conroy
Shannon M. Conroy
KPKathy L. Parsons
Kathy L. Parsons
DGDonna L. Gruol
Donna L. Gruol
A physiological role for cannabinoids in the CNS is indicated by the presence of endogenous cannabinoids and cannabinoid receptors. However, the cellular mechanisms of cannabinoid actions in the CNS have yet to be fully defined. In the current study, we identified a novel action of cannabinoids to enhance intracellular Ca2+responses in CNS neurons. Acute application of the cannabinoid receptor agonistsR(+)-methanandamide,R(+)-WIN, and HU-210 (1–50 nm) dose-dependently enhanced the peak amplitude of the Ca2+response elicited by stimulation of the NMDA subtype of glutamate receptors (NMDARs) in cerebellar granule neurons. The cannabinoid effect was blocked by the cannabinoid receptor antagonist SR141716A and the Gi/Goprotein inhibitor pertussis toxin but was not mimicked by the inactive cannabinoid analogS(−)-WIN, indicating the involvement of cannabinoid receptors. In current-clamp studies neitherR(+)-WIN norR(+)-methanandamide altered the membrane response to NMDA or passive membrane properties of granule neurons, suggesting that NMDARs are not the primary sites of cannabinoid action. Additional Ca2+imaging studies showed that cannabinoid enhancement of the Ca2+signal to NMDA did not involve N-, P-, or L-type Ca2+channels but was dependent on Ca2+release from intracellular stores. Moreover, the phospholipase C inhibitor U-73122 and the inositol 1,4,5-trisphosphate (IP3) receptor antagonist xestospongin C blocked the cannabinoid effect, suggesting that the cannabinoid enhancement of NMDA-evoked Ca2+signals results from enhanced release from IP3-sensitive Ca2+stores. These data suggest that the CNS cannabinoid system could serve a critical modulatory role in CNS neurons through the regulation of intracellular Ca2+signaling.

1 November 2011 in Women's Health
Verified
Journal Article
Open access
GMGertraud Maskarinec
Gertraud Maskarinec
CSCherisse Sen
Cherisse Sen
KKKarin Koga
Karin Koga
SCShannon M Conroy
Shannon M Conroy
Ethnic differences in breast cancer survival have been a long-standing concern. The objective of this article is to present relevant studies for all major US racial/ethnic groups including African–Americans, Latinos, Native Americans, Japanese–Americans and Native Hawaiians, and to discuss underlying causes of disparity, In comparison to Caucasian women, African–American women continue to experience the poorest breast cancer–specific survival of all ethnic groups in the USA. The prognosis for Latinos, Native Hawaiians and Native Americans is intermediate, better than for African–Americans but not as good as for Caucasians, whereas Japanese–American women tend to have better outcomes. The following possible contributors to the observed differences are discussed in detail: unfavorable distribution of stage at diagnosis due to low screening rates, limited access to care and treatment, tumor type, comorbidities, socioeconomic status, obesity and physical activity.

16 April 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
SCShannon M. Conroy
Shannon M. Conroy
GMGertraud Maskarinec
Gertraud Maskarinec
LWLynne R. Wilkens
Lynne R. Wilkens
KWKami K. White
Kami K. White
BHBrian E. Henderson
Brian E. Henderson
LKLaurence N. Kolonel
Laurence N. Kolonel

22 January 2013 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
GMGertraud Maskarinec
Gertraud Maskarinec
IPIan Pagano
Ian Pagano
MLMelissa A Little
Melissa A Little
SCShannon M Conroy
Shannon M Conroy
SPSong-Yi Park
Song-Yi Park
LKLaurence N Kolonel
Laurence N Kolonel
Introduction: Mammographic density, a strong predictor for breast cancer incidence, may also worsen prognosis in women with breast cancer. This prospective analysis explored the effect of prediagnostic mammographic density among 607 breast cancer cases diagnosed within the Hawaii component of the Multiethnic Cohort (MEC). Methods: Female MEC participants, aged ≥ 50 years at cohort entry, diagnosed with primary invasive breast cancer, and enrolled in a mammographic density case-control study were part of this analysis. At cohort entry, anthropometric and demographic information was collected by questionnaire. Tumor characteristics and vital status were available through linkage with the Hawaii Tumor Registry. Multiple digitized prediagnostic mammograms were assessed for mammographic density using a computer-assisted method. Cox proportional hazards regression was applied to examine the effect of mammographic density on breast cancer survival while adjusting for relevant covariates. Results: Of the 607 cases, 125 were diagnosed as in situ, 380 as localized, and 100 as regional/distant stage. After a mean follow-up time of 12.9 years, 27 deaths from breast cancer and 100 deaths from other causes had occurred; 71 second breast cancer primaries were diagnosed. In an overall model, mammographic density was not associated with breast cancer-specific survival (HR = 0.95 per 10%; 95%CI: 0.79-1.15), but the interaction with radiotherapy was highly significant (p = 0.006). In stratified models, percent density was associated with a reduced risk of dying from breast cancer (HR = 0.77; 95%CI: 0.60-0.99; p = 0.04) in women who had received radiation, but with an elevated risk (HR = 1.46; 95% CI: 1.00-2.14; p = 0.05) in patients who had not received radiation. High breast density predicted a borderline increase in risk for a second primary (HR = 1.72; 95% CI: 0.88-2.55; p = 0.15). Conclusions: Assessing mammographic density in women with breast cancer may identify women with a poorer prognosis and provide them with radiotherapy to improve outcomes.